Shenda Baker, Ph.D.
Chief Executive Officer
Dr. Shenda Baker is Chief Executive Officer of Synspira (interim). Dr. Baker has more than 25 years of experience in polymer chemistry and materials science and in leading, funding, and directing scientific research and development. She has extensive experience managing project execution, management of external consultants and advisors and business development efforts. She is President and COO of Synedgen Inc. Previously, she served as President of BioSTAR West, and as the lead scientific advisor to Hawaii Chitopure. She served on the Board of Directors of the Materials Research Society and has served on advisory boards with the National Institutes of Health, National Science Foundation and the Department of Energy. Dr. Baker is a member of the American Chemical Society and the Materials Research Society and currently serves on the Advisory Council of the National Institute of Dental and Craniofacial Research of the NIH. She is co-inventor on all Synspira technology.
Kim Snyder, MBA
Chief Financial Officer
Ms. Kim Snyder has extensive experience in financial reporting, budgeting and forecasting, mergers and acquisitions, and divestitures. Her industry experience includes public accounting, manufacturing, pharmaceutical and healthcare in for profit and not for profit organizations. Ms. Snyder holds a BA in Accounting & Business Management and an MBA with a focus on accounting and finance. As CFO she manages all contracts, investor funding, and financial planning and analysis.
Gregory Fiore MD
Chief Medical Advisor
Dr. Gregory Fiore is the lead Medical Advisor of Synspira as well as the CEO of Sollis Therapeutics. Dr. Fiore has founded two pharmaceutical consulting firms, Fiore Healthcare Advisors and SSI Strategy, and has spent many years in the pharmaceutical industry in a variety of leadership roles including Chief Medical Officer, Global Pharmacovigilance Head, and Clinical Program Lead. He has worked in such companies as Merck, The Medicines Company, and Abbott Laboratories and was a management consultant at McKinsey and Company before joining the pharmaceutical industry. He trained in Internal Medicine and Pulmonary Medicine at Harvard Medical School and received his medical degree from New York Medical College.
Christopher Ryan, Ph.D.
Director of Manufacturing
Dr. Christopher Ryan has extensive expertise in polysaccharide structural analysis and interactions of pathogens with human tissue. As Director of Pharmaceutical Manufacturing, Dr. Ryan has been involved in planning and implementing active pharmaceutical ingredient (API) manufacturing and medical device manufacturing. Manufacturing has met the requirements for use of API in non-clinical toxicology studies and clinical trials. He leads the manufacturing team in developing pilot scale batches of new products and provides expertise for scaling manufacturing processes for internal production and for external contract manufacture scale for marketed products. He has overseen contract manufacturing organizations to produce cosmetics, over-the-counter drugs, medical devices, and sterile drug product for clinical trials. He leads quality control personnel in the development of new testing procedures, qualification of equipment, and validation of test methods. He helped establish, and has since overseen, the implementation and continuous improvement of a cGMP quality system. He also helps lead the creation of regulatory affairs documentation to support submissions for medical devices and clinical trials. Dr. Ryan completed a postdoctoral fellowship at the University of California, Los Angeles, where he performed structural analysis of polysaccharide compounds and natural products from T. vaginalis and human pathogens as potential drug targets.